Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Minimally Invasive Surgery for Spontaneous Deep Intracerebral Hemorrhage (MIS-DEEP ICH)

28 september 2026 uppdaterad av: Tam Anh Research Institute

Effectiveness and Safety of Minimally Invasive Surgery for Spontaneous Deep Intracerebral Hemorrhage: A Prospective and Retrospective Observational Cohort Study

This observational cohort study evaluates the real-world effectiveness and safety of minimally invasive surgery (MIS) versus standard medical management in adults with spontaneous deep intracerebral hemorrhage. Patients presenting to Tam Anh General Hospital and People's Hospital 115 within 72 hours of hemorrhage onset will be enrolled and followed for 180 days. Clinical, radiological, and treatment-related variables will be collected, with primary outcome measures including survival and functional outcomes during follow-up period.

Studieöversikt

Detaljerad beskrivning

Spontaneous deep intracerebral hemorrhage (ICH) is a severe neurological condition associated with high mortality and significant long-term disability. Outcomes remain unsatisfactory with standard medical management alone, and conventional craniotomy has not consistently demonstrated a functional benefit. Minimally invasive surgery (MIS), including neuronavigation-guided parafascicular techniques, has been introduced to achieve hematoma evacuation while minimizing damage to surrounding brain structures and subcortical white-matter tracts. While increasing evidence supports the use of MIS in lobar ICH, evidence in patients with basal ganglia hemorrhage remains limited. In addition, previous studies have largely focused on surgery performed within the first 24 hours of symptom onset, and the effectiveness of MIS performed in the extended 24-to-72-hour window remains uncertain.

This retrospective and prospective, multicenter, observational cohort study is being conducted at Tam Anh General Hospital and People's Hospital 115. The study consists of both retrospective and prospective cohorts. The retrospective cohort includes patients treated from November 2024 onward, following approval by the Ministry of Health for the robotic-assisted intracerebral hematoma evacuation procedure at Tam Anh General Hospital, Ho Chi Minh City, and continues through the present. The prospective cohort is planned to enroll patients from June 2026 to June 2028. Eligible participants include those presenting with spontaneous basal ganglia ICH within 72 hours of symptom onset.

Management decisions, including the indication for MIS and the timing of surgical intervention, are determined solely by the treating physicians according to routine clinical practice. No treatment allocation or intervention is dictated by this protocol; instead, the study evaluates real-world clinical practices and outcomes.

Data will be recorded using standardized case report forms and electronic case report forms (CRFs/eCRFs). Collected information includes patient demographics, comorbidities, neurological presentation, laboratory results, radiological characteristics, intraoperative details for patients undergoing MIS, intensive care management, hospital course, and follow-up evaluations. All participants will be followed for 180 days after treatment.

The primary outcome measure is functional status at 180 days. Safety outcomes include mortality and treatment-related adverse events. Prespecified multivariable analyses will be conducted to address potential confounding by indication. Subgroup analyses are planned to compare outcomes according to the timing of MIS (0-24 hours versus 24-72 hours) and other clinically relevant factors.

By evaluating patients with basal ganglia hemorrhage treated across specialized Vietnamese stroke centers, this study seeks to provide real-world evidence regarding the effectiveness and safety of MIS for deep ICH and to support future research on patient selection and optimal timing of intervention.

Studietyp

Observationell

Inskrivning (Beräknad)

300

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Huy Tan Chu, MD-PhD
  • Telefonnummer: 1668 +842839976276
  • E-post: huyct@tamri.vn

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study population consists of adult patients with spontaneous basal ganglia intracerebral hemorrhage treated at participating stroke centers in Vietnam. Eligible patients are aged 18 to 80 years and have a diagnosis of spontaneous basal ganglia hemorrhage confirmed by non-contrast computed tomography (CT). Patients must have a hematoma volume between 30 and 80 mL, calculated using the ABC/2 method, and be enrolled within 72 hours of symptom onset (or last known well time if symptom onset is unknown). Additional eligibility criteria include a Glasgow Coma Scale (GCS) score between 5 and 14 and a pre-stroke modified Rankin Scale (mRS) score of 0 to 1. The study aims to evaluate the effectiveness and safety of minimally invasive surgery compared with standard medical treatment in a real-world clinical setting and to provide evidence regarding patient selection and optimal timing of intervention for deep intracerebral hemorrhage.

Beskrivning

Inclusion Criteria:

  • Age 18 to 80 years
  • Spontaneous basal ganglia intracerebral hemorrhage confirmed by non-contrast CT
  • Hematoma volume between 30 and 80 mL (calculated using the ABC/2 method)
  • Time from symptom onset to enrollment ≤ 72 hours (for patients with an unknown onset time, the last known well time will be used)
  • Glasgow Coma Scale (GCS) score between 5 and 14
  • Pre-stroke modified Rankin Scale (mRS) score of 0 to 1

Exclusion Criteria:

  • Secondary intracerebral hemorrhage due to trauma, brain tumor, arteriovenous malformation, cerebral aneurysm, or hemorrhagic transformation of ischemic stroke
  • Infratentorial hemorrhage involving the brainstem or cerebellum
  • Primary thalamic hemorrhage
  • Intraventricular extension occupying more than 50% of either lateral ventricle
  • NIHSS score < 5
  • Bilaterally fixed and dilated pupils with no light reflexes
  • Decerebrate posturing
  • Platelet count < 75,000/μL
  • IINR > 1.4 after correction
  • Ongoing anticoagulation that cannot be rapidly reversed
  • Indication for long-term anticoagulation within 5 days of symptom onset
  • End-stage renal disease
  • End-stage liver disease
  • Presence of a mechanical heart valve
  • Comorbid condition associated with a life expectancy < 6 months
  • Inability or unwillingness of the participant or legally authorized representative to provide written informed consent

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: OTHER

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
MIS Group

Participants with spontaneous deep intracerebral hemorrhage who receive standard medical treatment according to current clinical practice guidelines. Clinical and safety outcomes will be assessed through 180 days of follow-up.

Patients with spontaneous deep intracerebral hemorrhage who undergo minimally invasive surgery as part of routine clinical care. Decisions regarding surgical treatment and timing are made by the treating physicians according to standard practice. Clinical outcomes and safety outcomes will be evaluated through 180 days of follow-up.

Standard Medical Treatment Group

Participants with spontaneous deep intracerebral hemorrhage who receive standard medical treatment according to current clinical practice guidelines. Clinical and safety outcomes will be assessed through 180 days of follow-up.

Participants receive standard medical management according to current clinical practice guidelines for spontaneous intracerebral hemorrhage. Treatment decisions are made by the treating physicians. Clinical and safety outcomes will be evaluated through 180 days of follow-up.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Functional Outcome by modified Rankin Scale (mRS)
Tidsram: 180 days after symptom onset

Proportion of participants with a favorable functional outcome, defined as mRS score of 0 to 3.

Unit of Measure: Percentage of participants.

180 days after symptom onset
Functional Outcome by Utility-Weighted modified Rankin Scale (UW-mRS)
Tidsram: 180 days after symptom onset

Mean UW-mRS score at 180 days after symptom onset. The UW-mRS is a utility-based measure of functional outcome ranging from 0 (death) to 1 (no symptoms).

Unit of Measure: Score (range: 0 to 1)

180 days after symptom onset
Safety: All-Cause Mortality at 30 days
Tidsram: 30 days after symptom onset

All-cause mortality within 30 days after symptom onset. Unit of Measure: Percentage of participants

30 days after symptom onset
Safety: Change in Hematoma Volume (Δ volume)
Tidsram: Within 24 hours after MIS (MIS group) or within 6-36 hours after the baseline CT scan (standard medical treatment group)

Δ volume calculated as the difference between hematoma volume measured on the follow-up CT scan (performed within 24 hours after minimally invasive surgery (MIS) for MIS group, or within 6-36 hours after baseline CT scan for standard medical treatment group) and that on the baseline CT scan (the first CT scan performed on hospital admission). Hematoma volume will be measured using the ABC/2 method.

Unit of Measure: Milliliters (mL)

Within 24 hours after MIS (MIS group) or within 6-36 hours after the baseline CT scan (standard medical treatment group)
Safety: Treatment-Related Complications
Tidsram: From treatment initiation through 30 days after symptom onset

Occurrence of one or more treatment-related complications, including rebleeding, surgical site infection or meningitis, new-onset seizures, progressive cerebral edema, hydrocephalus requiring external ventricular drainage or shunt placement, hypotension or shock requiring specific treatment, and neurological readmission within 30 days.

Unit of Measure: Number of participants with one or more treatment-related complications

From treatment initiation through 30 days after symptom onset

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Functional Outcome According to Timing of Minimally Invasive Surgery (MIS)
Tidsram: 180 days after symptom onset

Among participants treated with minimally invasive surgery (MIS), the proportion achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-3 at 180 days, and the median modified Rankin Scale (mRS) score at 180 days will be compared between participants undergoing MIS within 24 hours of symptom onset and those undergoing MIS within >24-72 hours after symptom onset.

Unit of Measure: Percentage of participants; Score (range: 0 to 6)

180 days after symptom onset
Safety: All-Cause Mortality According to Timing of Minimally Invasive Surgery (MIS)
Tidsram: 30 days after symptom onset

Among participants treated with MIS, all-cause mortality within 30 days after symptom onset will be compared between those undergoing MIS within 0-24 hours of symptom onset and those undergoing MIS within >24-72 hours after symptom onset.

Unit of Measure: Percentage of participants

30 days after symptom onset
Safety: Treatment-Related Complications According to Timing of Minimally Invasive Surgery (MIS)
Tidsram: From treatment initiation through 30 days after symptom onset

Among participants treated with MIS, the occurrence of one or more treatment-related complications, including rebleeding, surgical site infection or meningitis, new-onset seizures, progressive cerebral edema, hydrocephalus requiring external ventricular drainage or shunt placement, hypotension or shock requiring specific treatment, and neurological readmission within 30 days, will be compared between those undergoing MIS within 24 hours of symptom onset and those undergoing MIS within >24-72 hours after symptom onset.

Unit of Measure: Number of participants with one or more treatment-related complications

From treatment initiation through 30 days after symptom onset

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 november 2026

Primärt slutförande (Beräknad)

31 december 2028

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

18 juni 2026

Först inskickad som uppfyllde QC-kriterierna

15 juli 2026

Första postat (Faktisk)

17 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

30 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 juni 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera